Zycubo, copper histidinate
Named-patient access overview. Zycubo is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Zycubo
Zycubo (copper histidinate) is manufactured by Sentynl Therapeutics and indicated for Menkes disease in pediatric patients. It is an oral small molecule approved by the US FDA in 2026 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Zycubo
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Zycubo for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Zycubo is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Zycubo in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Zycubo
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.